This phase III trial is trying to determine if giving neoadjuvant, then adjuvant immunotherapy will prolong survival in patients with early stage non-small cell lung cancer.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer
Bristol-Myers Squibb (BMS)
Eligible participants will be randomised to receive platinum-based doublet chemotherapy in combination with neoadjuvant and adjuvant nivolumab or a placebo at a specified dose on specified days.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More